<DOC>
	<DOCNO>NCT00176072</DOCNO>
	<brief_summary>Bioavailability methylene blue ( MB ) - comparison i.v . two oral MB formulation - influence sustain release MB chloroquine ( CQ ) concentration whole blood , plasma urine . Intraindividual cross open comparison healthy male female individual ( 6:6 ) different MB formulation randomise order determination absolute bioavailability MB ( part 1 ) , follow explorative randomised parallel group comparison CQ disposition CQ give alone ( 3 male 3 female ) combination 1000 mg sustain release MB ( 3 male 3 female ) participant study part 1 ( part 2 ) .</brief_summary>
	<brief_title>BlueCQ Bioavailability</brief_title>
	<detailed_description>Maximum whole blood methylene blue ( MB ) concentration i.v . oral administration may differ magnitude 100:1 . For achieve MB concentration possibly effective malaria use different pharmaceutical formulation , determination oral bioavailability MB necessary . To investigate 12 healthy subject ( 6 female , 6 male ) receive randomise cross design MB 50 mg i.v . MB 500 mg oral solution . For generate information plan phase II/III study Africa , intravenous oral MB preparation investigate . A second part study explorative investigate influence MB chloroquine ( CQ ) plasma concentration . During part 6 healthy subject ( 3 female , 6 male ) receive either CQ alone combination MB 500 mg , design part parallel design .</detailed_description>
	<criteria>Good state health physically mentally Any regular drug treatment currently past ( within last 2 month ) except oral contraceptive female Treatment know inhibitor inducer drug metabolise enzyme transport protein within period le 10 time respective elimination halflife Any acute chronic illness , especially : Glucose6phosphate dehydrogenase deficiency Allergic disposition history hypersensitivity reaction Smoking Alcohol drug abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>July 2004</verification_date>
</DOC>